Longtao Huangfu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Longtao Huangfu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Gangjian Wang
Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
3 shared publications Huanbo Zhu
3 shared publications- Junbing Chen
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Division of Gastrointestinal Cancer Translational Research Laboratory Peking University Cancer Hospital and Institute Beijing 100142 China
3 shared publications - Xiaofang Xing
Department of Gastrointestinal Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, China
3 shared publications Biao Fan
Department of Gastrointestinal Surgery Peking University Cancer Hospital and Institute Beijing 100142 China
2 shared publications- Jiafu Ji
Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Elsevier in Journal of Advanced Research
Cisplatin-Induced ecDNA Enhances Tumor Aggressiveness and Accelerates Chemoresistance Acquisition in Gastric Cancer
- 30 July 2026
- Published by Elsevier in Journal of Advanced Research
Open AccessCisplatin-Induced ecDNA Enhances Tumor Aggressiveness and Accelerates Chemoresistance Acquisition in Gastric Cancer
- Open Access
- 19 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e17380
TOPK Inhibition Promotes Anti‐Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer
Immune checkpoint blockade‐directed immunotherapy emerges as a revolutionary therapy in gastric cancer (GC). However, the proportion of patients who can benefit from it and its overall efficacy remain limited. Here the aim is to identify key dual‐function targets that both inhibit proliferation and suppress immune evasion. Using whole genome‐wide CRISPR‐Cas9‐based screening, the serine/threonine kinase T‐lymphokine‐activated killer cell‐originated protein kinase (TOPK) is identified as a key regulator of PD‐L1 in gastric cancer upon IFN‐γ stimulation. Mechanical study is performed to explore the role of TOPK in promoting GC malignancy and immune evasion in vitro and vivo. Higher TOPK levels in tumor tissues are observed, correlated with clinical stages, efficacy and survival. Upon IFN‐γ stimulation, TOPK phosphorylates eIF4F complex component eIF4A1 to increase its unwinding activity of STAT1 mRNA, enhancing STAT1 translation efficiency. This process leads to adaptive overexpression of PD‐L1 and IDO1, resulting in immunometabolic suppression through PD‐L1‐mediated inhibition, IDO1‐induced tryptophan depletion and kynurenine production. TOPK inhibitors reshape tumor immunometabolic microenvironment to trigger anti‐tumor immunity in GC. The IFN‐γ‐TOPK‐eIF4F‐STAT1‐PD‐L1/IDO1 axis as a crucial regulator of the tumor immunometabolic microenvironment and provide novel insights into the combination of targeted therapy and immunotherapy for GC treatment.
- 19 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e17380
Open AccessTOPK Inhibition Promotes Anti‐Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer
Immune checkpoint blockade‐directed immunotherapy emerges as a revolutionary therapy in gastric cancer (GC). However, the proportion of patients who can benefit from it and its overall efficacy remain limited. Here the aim is to identify key dual‐function targets that both inhibit proliferation and suppress immune evasion. Using whole genome‐wide CRISPR‐Cas9‐based screening, the serine/threonine kinase T‐lymphokine‐activated killer cell‐originated protein kinase (TOPK) is identified as a key regulator of PD‐L1 in gastric cancer upon IFN‐γ stimulation. Mechanical study is performed to explore the role of TOPK in promoting GC malignancy and immune evasion in vitro and vivo. Higher TOPK levels in tumor tissues are observed, correlated with clinical stages, efficacy and survival. Upon IFN‐γ stimulation, TOPK phosphorylates eIF4F complex component eIF4A1 to increase its unwinding activity of STAT1 mRNA, enhancing STAT1 translation efficiency. This process leads to adaptive overexpression of PD‐L1 and IDO1, resulting in immunometabolic suppression through PD‐L1‐mediated inhibition, IDO1‐induced tryptophan depletion and kynurenine production. TOPK inhibitors reshape tumor immunometabolic microenvironment to trigger anti‐tumor immunity in GC. The IFN‐γ‐TOPK‐eIF4F‐STAT1‐PD‐L1/IDO1 axis as a crucial regulator of the tumor immunometabolic microenvironment and provide novel insights into the combination of targeted therapy and immunotherapy for GC treatment.
- Open Access
- 20 August 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-15
The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling
Background: Ubiquitin-specific protease 15 (USP15) exhibits amplifications in various tumors, including gastric cancer (GC), yet its biological function and mechanisms in GC progression remain elusive. Methods: Here, we established stable USP15 knockdown or overexpression GC cell lines and explored the potential mechanism of USP15 in GC. Besides, we also identified interacting targets of USP15. Results: USP15 knockdown significantly impeded cell proliferation, invasion, epithelial-mesenchymal transition, and distal colonization in xenograft models, while enhancing oxaliplatin's antitumor effect. USP15 was involved in ubiquitination modification of glycolytic regulators. Silencing of USP15 suppressed glycolytic activity and impaired mitochondrial functions. Interference with USP15 expression reversed tumor progression and distal colonization in vivo. HKDC1 and IGF2BP3 were found as core interacting targets of USP15, and HKDC1 was identified as a substrate for ubiquitination modification by USP15, whereby USP15 regulated glucose metabolism activity by inhibiting the ubiquitination degradation of HKDC1. Conclusions: Our study unveiled aberrantly high expression of USP15 in GC tissues, correlating with malignant progression and nonresponse to neoadjuvant therapy. USP15 inhibitors, if developed, could be effective in promoting chemotherapy through glucose metabolism remodeling.
- 20 August 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-15
Open AccessThe deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling
Background: Ubiquitin-specific protease 15 (USP15) exhibits amplifications in various tumors, including gastric cancer (GC), yet its biological function and mechanisms in GC progression remain elusive. Methods: Here, we established stable USP15 knockdown or overexpression GC cell lines and explored the potential mechanism of USP15 in GC. Besides, we also identified interacting targets of USP15. Results: USP15 knockdown significantly impeded cell proliferation, invasion, epithelial-mesenchymal transition, and distal colonization in xenograft models, while enhancing oxaliplatin's antitumor effect. USP15 was involved in ubiquitination modification of glycolytic regulators. Silencing of USP15 suppressed glycolytic activity and impaired mitochondrial functions. Interference with USP15 expression reversed tumor progression and distal colonization in vivo. HKDC1 and IGF2BP3 were found as core interacting targets of USP15, and HKDC1 was identified as a substrate for ubiquitination modification by USP15, whereby USP15 regulated glucose metabolism activity by inhibiting the ubiquitination degradation of HKDC1. Conclusions: Our study unveiled aberrantly high expression of USP15 in GC tissues, correlating with malignant progression and nonresponse to neoadjuvant therapy. USP15 inhibitors, if developed, could be effective in promoting chemotherapy through glucose metabolism remodeling.
- Open Access
- 12 June 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 15893-15902
T‐cells infiltration mediates the association between neutrophil/lymphocyte ratio and survival in gastric cancer
Background: Neutrophil/lymphocyte ratio (NLR) is a vital index for systemic inflammation and a prognostic indicator for gastric cancer (GC). Despite the abundant literature on NLR's prognostic value for GC, the underlying factors mediating its impact on survival remain unclear. The objective of this study was to analyze the role of NLR in different prognostic models and subgroups, and investigate the mediating effects of immune infiltrates between NLR and survival.Methods: A total of 924 patients who underwent D2 lymph node resection were enrolled in this study. According to the level of NLR, patients were divided into two groups, the high and low NLR groups. Clinical parameters, indexes related to immune infiltrates, and survival were compared between the two groups. Prognostic models, interaction analysis, and mediating effects analysis were performed to investigate the clinical association of NLR, immune infiltrates, and survival.Results: The infiltration of CD3+ and CD8+ T cells was significantly different in the two NLR groups. The level of NLR was an independent prognostic predictor of GC. In addition, an interaction effect exists between NLR and MMR status on the prognosis of GC (p‐interaction p < 0.001).Conclusions: The level of NLR is an independent prognostic predictor of GC. The effect of NLR on prognosis is partly mediated by CD3+ T‐cell infiltration.
- 12 June 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 15893-15902
Open AccessT‐cells infiltration mediates the association between neutrophil/lymphocyte ratio and survival in gastric cancer
Background: Neutrophil/lymphocyte ratio (NLR) is a vital index for systemic inflammation and a prognostic indicator for gastric cancer (GC). Despite the abundant literature on NLR's prognostic value for GC, the underlying factors mediating its impact on survival remain unclear. The objective of this study was to analyze the role of NLR in different prognostic models and subgroups, and investigate the mediating effects of immune infiltrates between NLR and survival.Methods: A total of 924 patients who underwent D2 lymph node resection were enrolled in this study. According to the level of NLR, patients were divided into two groups, the high and low NLR groups. Clinical parameters, indexes related to immune infiltrates, and survival were compared between the two groups. Prognostic models, interaction analysis, and mediating effects analysis were performed to investigate the clinical association of NLR, immune infiltrates, and survival.Results: The infiltration of CD3+ and CD8+ T cells was significantly different in the two NLR groups. The level of NLR was an independent prognostic predictor of GC. In addition, an interaction effect exists between NLR and MMR status on the prognosis of GC (p‐interaction p < 0.001).Conclusions: The level of NLR is an independent prognostic predictor of GC. The effect of NLR on prognosis is partly mediated by CD3+ T‐cell infiltration.